Windham Venture Partners — Activity | F4Windham Venture Partners Activity
Every public signal F4 has attached to this firm, with sources and cross-entity links.
Milestone
FORE Biotherapeutics received Breakthrough Therapy Designation for Plixorafenib from FDA.
Fore Biotherapeutics
Dr. Alistair Erskine, Chief Digital Officer and Chief Information Officer of Emory University, appointed as Operating Partner.
Dr. Alistair Erskine appointed Operating Partner
Team Change
Jason Helgerson, former New York Medicaid Director, appointed as Operating Partner.
Jason Helgerson appointed Operating Partner
5 milestones· JUN 2025 – OCT 2025Show all
Milestone
Alto Neuroscience announced plans to accelerate development of ALTO-207 in treatment-resistant depression following FDA meeting.
Alton Neuroscience
Milestone
PainTEQ secured majority growth recapitalization co-led by Signet Healthcare Partners and Windham Capital Partners.
PainTEQ
Milestone
CVRx announced positive news on outpatient payment for Barostim therapy, improving reimbursement landscape.
CVRx
Milestone
Neuspera Medical received FDA approval for its integrated sacral neuromodulation system for urinary urge incontinence.
NeuSpera
Milestone
Valera Health expanded mental health services with acquisition of Vita Health, including suicide prevention programs.
Valera Health